HDAC9 and melanoma: Treatment of resistant melanoma cells with the pan-HDAC inhibitor vorinostat downregulated SLC7A11 (the gene of the cysteine-glutamate antiporter xCT), which further increased intracellular ROS levels to a cytotoxic level specifically in the drug-resistant cells, triggering apoptosis [Table 2 and Figure 3].